FOXO4-DRI and senolytic peptides: one mouse paper and a market
Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board
- FOXO4-DRI is a peptide designed to make senescent, or 'zombie', cells self-destruct by freeing p53. A 2017 study in Cell showed it restored fitness, fur and kidney function in aged mice.
- Everything since has been in cells and mice. No human trial has been published or is registered, and FDA has approved no FOXO4-DRI product.
- Senolytic drugs such as dasatinib plus quercetin have reached small human trials with mixed results, and in a mouse study clearing senescent cells, including with FOXO4-DRI itself, worsened pulmonary hypertension.
Senescent cells and the senolytic idea
Senescent cells are damaged cells that have stopped dividing but resist programmed cell death 1 2. They accumulate with age 3, secrete inflammatory signals known as the senescence-associated secretory phenotype 4, and are thought to impair tissue function; removing them genetically in mice delays features of ageing 1. That raised a possibility: a drug that selectively killed senescent cells, a senolytic, might treat several age-related conditions at once.
The challenge is selectivity: a senolytic has to overcome senescent cells' resistance to apoptosis without harming healthy cells 1. Small-molecule senolytics include dasatinib plus quercetin 5, fisetin 2 and ABT263 6. FOXO4-DRI took a different approach.
What FOXO4-DRI is
In senescent cells, the protein FOXO4 binds p53 in the nucleus and so prevents the cell's apoptosis 7. In 2017, Baar and colleagues designed a peptide that interferes with that interaction. In senescent cells it caused p53 to leave the nucleus and set off cell-intrinsic apoptosis, while sparing normal cells 1.
The peptide is made from D-amino acids, the mirror images of the amino acids in natural proteins, assembled in reverse order, a 'D-retro-inverso' design that its authors chose because it can give a peptide new chemical properties that may improve its potency and stability; the peptide and the mice used were the subject of patent applications 1. It carries a positively charged cell-penetrating segment 8. A 2025 study solved the structure of its interaction: the disordered FOXO4-DRI binds a disordered region of p53 and forms a transiently folded complex, with both the FOXO4-derived part and the cell-penetrating part contributing; the paper's FOXO4-DRI co-author lists an affiliation with Cleara Biotech 8.
The 2017 mouse study
The results that made headlines came from mice. Under conditions where it was well tolerated, FOXO4-DRI neutralised the toxicity of the chemotherapy drug doxorubicin, and it restored fitness, fur density and kidney function both in mice engineered to age rapidly and in naturally aged mice 1. For a field searching for a way to clear senescent cells selectively, it was a striking demonstration.
It was also one study, in mice, from the group that designed the peptide 1. Its doses, schedules and safety findings apply to mice, and no study has measured how the peptide is absorbed, distributed or tolerated in a person.
What has followed
Since 2017, FOXO4-DRI has been studied in cells and animals for a range of conditions 9 10 11 7 12 8:
| Year | Study | Model | What it showed |
|---|---|---|---|
| 2017 | Baar et al., Cell | Cells; fast-ageing and naturally aged mice | Peptide killed senescent cells; restored fitness, fur and kidney function in mice |
| 2020 | Leydig cells | Cells; aged mice | Improved testosterone secretion in aged mice |
| 2021 | Chondrocytes | Human cartilage cells in culture | Removed senescent cells from expanded chondrocytes; did not improve cartilage formation |
| 2022-2023 | Lung fibrosis | Mice | Reduced bleomycin-induced fibrosis |
| 2024 | Sperm production | Aged mice | Improved spermatogenesis |
| 2025 | Keloids; structure | Human keloid fibroblasts and organ cultures; NMR | Killed senescent keloid fibroblasts; mapped binding to p53 |
| 2026 | People | None | No published or registered human trial |
In aged mice, it improved testosterone secretion by targeting senescent Leydig cells in the testes 9 and improved sperm production 7. In human cartilage cells grown in the laboratory for transplantation, it removed more than half of the heavily expanded cells and lowered their senescence, but did not improve their ability to form cartilage 10. In mice with chemically induced lung scarring, it reduced fibrosis 11 13, and in human keloid fibroblasts it induced apoptosis of senescent cells 12. Every one of these is a cell or animal study. On October 27, 2026, ClinicalTrials.gov listed no study of FOXO4-DRI 14, and Drugs@FDA listed no FOXO4-DRI product 15.
Is clearing senescent cells always good?
Not necessarily. A 2023 study in Circulation found that in mice, eliminating senescent cells with a genetic 'suicide' switch or the senolytic drug ABT263 increased pressure in the right side of the heart, worsened vessel remodelling and markedly reduced the lung's endothelial cells. FOXO4-DRI was tested too: in mice engineered to overexpress the serotonin transporter, a pulmonary hypertension model, it was followed, as ABT263 was, by pulmonary haemodynamic alterations and loss of lung endothelial cells compared with controls, and the authors concluded that eliminating senescent endothelial cells may worsen pulmonary haemodynamics 6. A drug that kills cells is not automatically rejuvenating.
How senolytic drugs have fared in people
The small-molecule senolytics have at least reached people, and their results are a useful reality check. In a phase 1 pilot in 12 people with idiopathic pulmonary fibrosis, intermittent dasatinib plus quercetin was feasible and generally tolerated, with no serious adverse events attributed to it, but sleep disturbance and anxiety were more common (4 of 6 against 0 of 6), and frailty, lung and physical function did not appear to differ, in a trial too small to tell 5. In a phase 2 randomised trial in 60 postmenopausal women, intermittent dasatinib plus quercetin did not change the primary bone-resorption marker at 20 weeks, though a bone-formation marker rose early 3. A 2022 paper describes an open-label pilot in five older adults with early Alzheimer's disease designed to test whether the combination reaches the cerebrospinal fluid 16. A related senolytic that blocks the p53-MDM2 interaction, UBX0101, reduced oxidative damage in aged mouse knees, with weaker benefit in old animals than young 17. Fisetin, a senolytic flavonoid, is being tested in a multicentre randomised phase 2 trial in 220 patients over 65 with sepsis, according to its 2024 protocol 2.
Those are modest, early results. FOXO4-DRI has no published human pharmacology and no human safety data.
The measurement problem
Even for the senolytics in human trials, a basic question is hard: how many senescent cells does a person have, and did the drug remove them? In mice, researchers can count cells in tissue; in people, they need blood markers. Investigators from the postmenopausal bone trial reported that women whose T cells expressed the most of one form of the senescence marker p16 had the strongest bone responses to dasatinib plus quercetin, and that a panel of inflammatory proteins secreted by senescent cells in plasma performed as well at identifying them 4. That is progress towards selecting the right people for trials. Until such markers are validated, a claim that a product has cleared senescent cells in a particular person cannot be checked.
Questions to ask about any anti-ageing peptide
- Has it been given to people in a published study, and what did that study measure: a disease outcome, a blood marker, or nothing beyond safety?
- Who did the research? A single group, or independent laboratories that reproduced it?
- Is the human claim backed by a human study, or only by mice and cells?
- For a product designed to kill cells or change cell survival, what is known about effects on tissues the marketing does not mention?
- Can the seller show, from an identified laboratory, that the vial contains the right molecule, including the correct mirror-image amino acids?
For FOXO4-DRI, the answers are no human study, one designing group for the key result with independent cell and mouse follow-ups 9 10 11, mouse evidence only, a mouse study in which it worsened pulmonary hypertension 6, and no published human data on anything else.
Outside the laboratory
A vial labelled FOXO4-DRI cannot show, without specialist testing, whether it holds the D-retro-inverso peptide the studies used rather than the same sequence in ordinary L-amino acids or something else entirely. And because the peptide is designed to kill cells, a mistake in dose or selectivity is not a trivial risk. For athletes, WADA's 2026 List does not name FOXO4-DRI, but its S0 class prohibits at all times any pharmacological substance not addressed elsewhere on the List "and with no current approval by any governmental regulatory health authority for human therapeutic use" 18.
Other ageing-related peptides are sold the same way. Our entries on humanin and MOTS-c set out how far each has got, and our guide to reading a study explains why a single mouse paper is the start of a research programme, not evidence of a human benefit.
Why there is no human trial
Moving a compound like FOXO4-DRI into people would require manufacturing to pharmaceutical standards, toxicology studies in two species, and careful dose-finding, because a peptide that triggers cell death could cause harm if it is less selective in human tissue than in mouse cells. The 2017 authors described it as well tolerated under the conditions they used in mice 1, which is a starting point for that work, not a substitute for it. Until such studies are done and published, what FOXO4-DRI does in people is unknown.
The bottom line
As of October 27, 2026, FOXO4-DRI is a research peptide with a 2017 mouse study in Cell 1, a solved structure 8 and a string of cell and animal follow-ups. It has not been given to a person in a published study, and FDA has approved no FOXO4-DRI product 15. Senolytic drugs that have reached people have produced mixed, early results 5 3, and clearing senescent cells, with FOXO4-DRI among the tools, worsened pulmonary hypertension in mice 6. A vial labelled FOXO4-DRI offers a peptide of unverified identity, designed to kill cells, with no human safety data.
Frequently asked questions
What is FOXO4-DRI?
A synthetic D-retro-inverso peptide designed to block FOXO4 from binding p53 in senescent cells, so that those cells undergo apoptosis. It was described in a 2017 mouse study.
Has FOXO4-DRI been tested in humans?
No. As of October 27, 2026, no human trial has been published or is registered on ClinicalTrials.gov, and Drugs@FDA lists no FOXO4-DRI product.
Do senolytics work in people?
Small trials of senolytic drugs such as dasatinib plus quercetin have shown feasibility but mixed results; a 60-woman bone trial missed its primary endpoint.
Is removing senescent cells safe?
Not always. In a 2023 mouse study, eliminating senescent cells with a suicide gene, ABT263 or FOXO4-DRI worsened pulmonary hypertension.
Related on Grey Peptides
Sources
- Baar, M. P., et al. (2017). Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell, 169(1), 132-147.e16. PMID: 28340339
- Silva, M., et al. (2024). Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multicenter, randomized, adaptive allocation clinical trial. Trials, 25(1), 698. PMID: 39434114
- Farr, J. N., et al. (2024). Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med, 30(9), 2605-2612. PMID: 38956196
- Farr, J. N., et al. (2025). Characterization of Human Senescent Cell Biomarkers for Clinical Trials. Aging Cell, 24(5), e14489. PMID: 39823170
- Nambiar, A., et al. (2023). Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. EBioMedicine, 90, 104481. PMID: 36857968
- Born, E., et al. (2023). Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation, 147(8), 650-666. PMID: 36515093
- Li, Y., et al. (2024). FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Exp Gerontol, 195, 112522. PMID: 39025385
- Bourgeois, B., et al. (2025). The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun, 16(1), 5672. PMID: 40593617
- Zhang, C., et al. (2020). FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY), 12(2), 1272-1284. PMID: 31959736
- Huang, Y., et al. (2021). Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Front Bioeng Biotechnol, 9, 677576. PMID: 33996787
- Han, X., et al. (2022). FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. J Cell Mol Med, 26(11), 3269-3280. PMID: 35510614
- Kong, Y. X., et al. (2025). FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol, 8(1), 299. PMID: 39994346
- Liu, Y., et al. (2023). FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Naunyn Schmiedebergs Arch Pharmacol, 396(10), 2393-2403. PMID: 37074394
- ClinicalTrials.gov search (API v2) for 'FOXO4-DRI' and 'proxofim', October 27, 2026: no registered studies. ClinicalTrials.gov
- US FDA, Drugs@FDA via openFDA (drugsfda endpoint), search for FOXO4, October 27, 2026: no matching product. FDA
- Gonzales, M. M., et al. (2022). Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial. J Prev Alzheimers Dis, 9(1), 22-29. PMID: 35098970
- Chin, A. F., et al. (2023). Senolytic treatment reduces oxidative protein stress in an aging male murine model of post-traumatic osteoarthritis. Aging Cell, 22(11), e13979. PMID: 37749958
- World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026: S0 (non-approved substances), prohibited at all times; FOXO4-DRI not named. Read October 27, 2026. WADA
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead